Go Pro
OTCMKTS:INNVD

Innovus Pharmaceuticals (INNVD) Stock Price, News & Analysis

Innovus Pharmaceuticals logo

About Innovus Pharmaceuticals Stock (OTCMKTS:INNVD)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
4,300 shs
Average Volume
9,592 shs
Market Capitalization
$7.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Receive INNVD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innovus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INNVD Stock News Headlines

Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
See More Headlines

INNVD Stock Analysis - Frequently Asked Questions

Innovus Pharmaceuticals Inc (OTCMKTS:INNVD) announced its earnings results on Monday, April, 1st. The company reported ($0.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.12. The firm earned $4.75 million during the quarter, compared to analyst estimates of $8.13 million. Innovus Pharmaceuticals had a negative trailing twelve-month return on equity of 682.54% and a negative net margin of 34.51%.

Shares of INNVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
4/01/2019
Today
8/12/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:INNVD
CIK
N/A
Fax
N/A
Employees
12
Year Founded
2011

Profitability

EPS (Trailing Twelve Months)
($4.16)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.28 million
Net Margins
-34.51%
Pretax Margin
N/A
Return on Equity
-682.54%
Return on Assets
-78.57%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.68
Quick Ratio
0.36

Sales & Book Value

Annual Sales
$23.99 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.05 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
2,356,000
Free Float
N/A
Market Cap
$7.07 million
Optionable
Not Optionable
Beta
2.89

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (OTCMKTS:INNVD) was last updated on 8/12/2026 by MarketBeat.com Staff.
From Our Partners